CBD may boost cancer immunity by altering tumor cells' immune invisibility

This study examined how CBD (cannabidiol), a major non-intoxicating compound in cannabis, affects immune-related molecules on cancer cells. Specifically, researchers investigated how CBD influences HLA (human leukocyte antigen) proteins, which are crucial for the immune system to recognize and attack abnormal cells like cancer. The team used a cell line derived from choriocarcinoma (placental cancer) to explore these effects, discovering that CBD increased classical HLA class I expression while reducing HLA-G levels, a non-classical HLA molecule that helps tumors hide from immune surveillance.

The research revealed a sophisticated mechanism involving multiple receptor pathways and calcium signaling. CBD activated several cannabinoid-related receptors (CB1, CB2, GPR55, and PPAR-gamma) that appeared to work through distinct pathways—with CB1 primarily involved in reducing the immunosuppressive HLA-G, while CB2 and GPR55 contributed to increasing classical HLA expression. These findings suggest that CBD may promote anti-tumor immune responses by shifting the immune "visibility" of cancer cells, potentially making them more recognizable to the immune system while reducing their natural camouflage mechanisms.

This research carries significant implications for understanding how cannabis compounds might support immune function against tumors. While these results are from laboratory cell studies rather than human trials, they suggest that CBD's effects on HLA expression could represent a novel immunomodulatory mechanism worth exploring in cancer contexts. Further research in animal models and eventually clinical settings could determine whether CBD might complement conventional cancer treatments by enhancing immune recognition of malignant cells.